Keros Therapeutics (KROS) KER-050 Data Shows Strong PoC Efficacy - Jefferies
Tweet Send to a Friend
Jefferies analyst Eun Yang reiterated a Buy rating and $70.00 price target on Keros Therapeutics (NASDAQ: KROS) after preliminary KER-050 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
